Clinical Application of Bone Marrow Implantation in Patients With Arteriosclerosis Obliterans, and the Association Between Efficacy and the Number of Implanted Bone Marrow Cells
Open Access
- 1 January 2004
- journal article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 68 (12) , 1189-1193
- https://doi.org/10.1253/circj.68.1189
Abstract
Background There have been a number of recent reports on the use of autologous bone marrow implantation (BMI) in the treatment of peripheral arterial disease, with a clinical response rate of approximately 70%. However, the factors that influence efficacy have not yet been clarified. We have analyzed the relationship between the number of implanted bone marrow cells and the clinical efficacy of BMI. Methods and Results Eight patients with arteriosclerosis obliterans were treated with BMI. Bone marrow was aspirated from the ilium (500-1,000 ml), the mononuclear cells were separated and then were implanted. The clinical effectiveness of BMI was evaluated by assessing changes in the ankle-brachial pressure index (ABI) and the transcutaneous oxygen pressure (TcO2) between the pre-treatment baseline, with follow-up testing at 4 weeks. These changes were defined as ΔABI and ΔTcO 2. The mean number of CD34-positive cells was 1.04±0.60 ×106 /kg body weight. There was a strong correlation between the number of CD34-positive cells and ΔABI (r=0.754, p=0.028). Conclusions It is likely that the number of implanted CD34-positive cells is one of the primary factors that influence the clinical efficacy of BMI. (Circ J 2004; 68: 1189 - 1193)Keywords
This publication has 14 references indexed in Scilit:
- Bone Marrow Monocyte Lineage Cells Adhere on Injured Endothelium in a Monocyte Chemoattractant Protein-1–Dependent Manner and Accelerate Reendothelialization as Endothelial Progenitor CellsCirculation Research, 2003
- Regional Angiogenesis With Vascular Endothelial Growth Factor in Peripheral Arterial DiseaseCirculation, 2003
- Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trialVascular Medicine, 2003
- Molecular Strategies to Treat Vascular Diseases-Circulating Vascular Progenitor Cell as a Potential Target for Prophylactic Treatment of Atherosclerosis-Circulation Journal, 2003
- Peripheral-blood or bone-marrow mononuclear cells for therapeutic angiogenesis?The Lancet, 2002
- Improvement of Collateral Perfusion and Regional Function by Implantation of Peripheral Blood Mononuclear Cells Into Ischemic Hibernating MyocardiumArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Angiogenesis by Implantation of Peripheral Blood Mononuclear Cells and Platelets Into Ischemic LimbsCirculation, 2002
- Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trialThe Lancet, 2002
- A 1: Objectives and methodology of the consensus processJournal of Vascular Surgery, 2000
- Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularizationJournal of Clinical Investigation, 1999